葛军娜;于健春;康维明;马志强;

• 1:中国医学科学院北京协和医学院北京协和医院基本外科

摘要(Abstract)：

<正>肿瘤相关性贫血指因为肿瘤或放化疗引起的红细胞数量减少或血红蛋白低下[1]。早在19世纪人们就认识到肿瘤相关性贫血[2],但直到最近15年其病理生理学机制才逐渐清晰。肿瘤相关性贫血的特征是

关键词(KeyWords)： 炎性因子;肿瘤相关性贫血;铁调素

Abstract:

Keywords:

基金项目(Foundation): “十一五”国家科技支撑计划项目(2008BAI58B02)

作者(Author): 葛军娜;于健春;康维明;马志强;

Email:

DOI:

参考文献(References)：

• [1]Koeller JM.Clinical guidelines for the treatment of cancer related anemia[J].Pharmacotherapy,1998,18:156-169.
• [2]Crosby WH,Akeroyd JH.The limit of hemoglobin synthesis in hereditary hemolytic anemia;its relation to the excretion of bile pigment[J].Am J Med,1952,13:273-283.
• [3]Hyman GA.Anemia in malignant neoplastic disease[J].J Chronic Dis,1963,16:645-666.
• [4]Lawrence T.Anemia of chronic disease[J].N Engl J Med,2005,352:1011-1023.
• [5]Badzek S,Curic′Z,Krajina Z,et al.Treatment of Cancer-Related Anemia[J].Coll Antropol,2008,32:615-622.
• [6]Nemeth E,Ganz T.The role of hepcidin in iron metabolism[J].Acta Haematol,2009,122:78-86.
• [7]Sasu BJ,Li H,Rose MJ,et al.Serumhepcidin but not pro-hepcidin may be an effective marker for anemia of inflamma-tion(AI)[J].Blood Cells Mol Dis,2010,45:238-245.
• [8]Rivera S,Liu L,Nemeth E,et al.Hepcidin excess induces the sequestration of iron and exacerbates tumor-associated a-nemia[J].Blood,2005,105:1797-1802.
• [9]Jong D,Eijkemans MJ,Lie Fong S,etal.Preoperative pre-dictors for residual tumor after surgery in patients with ovari-an carcinoma[J].Oncology,2007,72:293-301.
• [10]Adamson JW.The anemia of inflammation/malignancy:mechanisms and management[J].Hematol Am Soc Hema-tol Educ Program,2008,159-165.
• [11]Ryan JL,Carroll JK,Ryan EP,etal.Mechanisms of Canc-er-Related Fatigue[J].Oncologist,2007,12(Suppl1):22-34.
• [12]Groopman JE,Itri LM.Chemotherapy-induced anemia in a-dults:incidence and treatment[J].J Natl Cancer Inst,1999,91:1616-1634.
• [13]Kawada N,Moriyama T,Ichimaru N,etal.Negative effects of anemia on quality of life and its improvement by complete correction of anemia by administration of recombinant human erythropoietin in posttransplant patients[J].Clin Exp Nephrol,2009,13:355-360.
• [14]Ludwig H,Van Belle S,Barrett-Lee P,etal.The European Cancer Anaemia Survey(ECAS):a large,multinational,prospective survey defining the prevalence,incidence,and treatment of anemia in cancer patients[J].Eur J Cancer,2004,40:2293-2306.
• [15]Glaspy J,Meza L,Smith R,et al.Openlabel,phase I/II dose escalation study of ARANESP in patients with chronic anemia of cancer[J].Blood,2000,96:154b.
• [16]Wenzel LB,Huang HQ,Armstrong DK,et al.Health-relat-ed quality of life during and after intraperitoneal versus intra-venous chemotherapy for optimally debulked ovarian cancer:a gynecologic oncology group study[J].J Clin Oncol,2007,25:437-443.
• [17]Cella D,Kallich J,McDermottA,etal.Relationship of he-moglobin,fatigue,and quality of life in anemic cancer pa-tients[J].Ann Oncol,2004,15:979-986.
• [18]Caro JJ,Salas M,Ward A,et al.Anemia as an independ-ent prognostic factor for survival in patients with cancer:a systemic,quantitative review[J].Cancer,2001,91:2214-2221.
• [19]Dubsky P,Sevelda P,Jakesz R,et al.Anemia Is a signifi-cant prognostic factor in local relapse-free survival of prem-enopausal primary breast cancer patients receiving adjuvant cyclophosphamide/methotrexate/5-fluorouracil chemotherapy[J].Clin Cancer Res,2008,14:2082-2087.
• [20]Lee SD,Park JW,Park KS,et al.Influence of anemia on tumor response to preoperative chemoradiotherapy for locally advanced rectal cancer[J].Int J Colorectal Dis,2009,24:1451-1458.
• [21]Dubray B,Mosseri V,Brunin F,et al.Anemia is associat-ed with lower local-regional control and survival after radia-tion therapy for head and neck cancer:a prospective study[J].Radiology,1996,201:553-558.
• [22]Rockwell S,Dobrucki IT,Kim EY,et al.Hypoxia and ra-diation therapy:Past history,ongoing research,and futurepromise[J].Curr Mol Med,2009,9:442-458.
• [23]Vaupel P,Mayer A.Hypoxia in cancer:significance and impact on clinical outcome[J].Cancer Metastasis Rev,2007,26:225-239.
• [24]Fyles AW,Milosevic M,Wong R,et al.Oxygenation pre-dicts radiation response and survival in patients with cervix cancer[J].Radiother Oncol,1998,48:149-156.
• [25]Lin FK,Suggs S,Lin CH,et al.Cloning and expression of the human erythropoietin gene[J].Proc Natl Acad Sci USA,1985,82:7580-7584.
• [26]Dagnelie PC,Pijls-Johannesma MC,Lambin P,et al.Im-pact of fatigue on overall quality of life in lung and breast cancer patients selected for high-dose radiotherapy[J].Ann Oncol.2007,18:940-944.
• [27]Bohlius J,Wilson J,Seidenfeld J,et al.Recombinant hu-man erythropoietins and cancer patients:updated meta-anal-ysis of57studies including9353patients[J].J Natl Canc-er Inst,2006,17:708-714.
• [28]Fandrey J.Erythropoietin receptors on tumor cells:what do they mean[J].Oncologist,2008,13Suppl3:16-20.
• [29]Fu P,Jiang X,Arcasoy MO.Constitutively active erythro-poietin receptor expression in breast cancer cells promotes cellular proliferation and migration through a MAP-kinase dependent pathway[J].Biochem Biophys Res Commun,2009,379:696-701.
• [30]Kumar SM,Acs G,Fang D,etal.Functional erythropoietin autocrine loop in melanoma[J].Am J Pathol,2005,166:823-830.
• [31]Brown WM,Maxwell P,Graham AN,et al.Erythropoietin receptor expression in non-small cell lung carcinoma:a question of antibody specificity[J].Stem Cells,2007,25:718-722.
• [32]Lai SY,Childs EE,Xi S,et al.Erythropoietin-mediated activation of JAK-STATsignaling contributes to cellularinva-sion in head and neck squamous cell carcinoma[J].Onco-gene,2005,24:4442-4449.
• [33]Pangalis GA,Siakantaris MP,Angelopoulou MK.Down-staging Rai stage IIIB chronic lymphocytic leukemia patients with the administration of recombinant human erythropoietin[J].Haematologica,2002,87:500-506.
• [34]Jia HB,Jin Y,Ji Q,et al.Effects of recombinant human erythropoietin on neuropathic pain and cerebral expressions of cytokines and nuclear factor-kappa B[J].Can J An-aesth,2009,56:597-603.
• [35]National Blood Data Resource Center.FAQs[DB/OL].(2006-06-12)http://www.aabb.org/Documents/Programs-and-Services/NBDRC/faqs.htm.
• [36]Goodnough LT,Brecher ME,Kanter MH,et al.Transfu-sion medicine.First of two parts—blood transfusion[J].N Engl J Med,1999,340:438-447.
• [37]von Ahsen N,Muller C,Serke S,et al.Important role of nondiagnostic blood loss and blunted erythropoietic response in the anemia of medical intensive care patients[J].Crit Care Med,1999,27:2630-2639.
• [38]Corwin HL,GettingerA,Pearl RG,etal.The CRITStudy:Anemia and blood transfusion in the critically ill--current clinical practice in the United States[J].Crit Care Med,2004,32:39-52.
• [39]Bierbaum BE,Callaghan JJ,Galante JO,et al.An analysis of blood management in patients having a total hip or knee arthroplasty[J].J Bone Joint Surg Am,1999,81:2-10.
• [40]Wu WC,Smith TS,Henderson WG,et al.Operative blood loss,blood transfusion,and30-day mortality in older pa-tients after major noncardiac surgery[J].Ann Surg,2010,252:11-17.
• [41]Shiba H,Ishida Y,Wakiyama S,et al.Negative impact of blood transfusion on recurrence and prognosis of hepatocellu-lar carcinoma after hepatic resection[J].J Gastrointest Surg,2009,13:1636-1642.
• [42]Benson D,Barnett CC Jr.Perioperative blood transfusions promote pancreas cancer progression[J/OL].J Surg Res(2010-06-17).http://www.journalofsurgicalresearch.com/search/quick.
• [43]Atzil S,Arad M,Glasner A,et al.Blood transfusion pro-motes cancer progression:a critical role for aged erythro-cytes[J].Anesthesiology,2008,109:989-997.
• [44]Ojima T,Iwahashi M,Nakamori M,etal.Association of al-logeneic blood transfusions and long-term survival of patients with gastric cancer after curative gastrectomy[J].J Gas-trointest Surg,2009,13:1821-1830.
• [45]National Comprehensive Cancer Network.Comments in re-sponse to the proposed decision memo(CAG00383N)for erythropoiesis stimulating agents(ESAs)for non-renal dis-ease indications[DB/OL].(2007-06-12).http://www.nccn.org/professionals/physician-gls/PDF/mds.pdf.
• [46]Kaye P,Abdulla K,Wood J,et al.Iron-induced mucosal pathology of the upper gastrointestinal tract:a common find-ing in patients on oral iron therapy[J].Histopathology,2008,53:311-317.
• [47]Rozen-Zvi B,Gafter-Gvili A,Paul M,et al.Intravenous Versus oral iron supplementation for the treatment of anemia in CKD:systematic review and meta-analysis[J].Am J Kidney Dis,2008,52:897-906.
• [48]Auerbach M,Ballard H,Glaspy J.Clinical update:intrave-nous iron foranaemia[J].Lancet,2007,369:1502-1504.
• [49]Chao-Hung Ho,Yuan-Bin Yu,Ping-Hao.The prevalence of iron deficiency anemia and its clinical implications in pa-tients with colorectal carcinoma[J].J Chin Med Assoc,2008,71:119-122.
• [50]Sworczak K,Siekierska HM,Drobinska A,et al.Iron defi-ciency anemia as the sole symptomof small intestine carcino-ma[J].Med Sci Monit,2001,7:457-460.
• [51]Carter D,Maor Y,Bar-Meir S,et al.Prevalence and pre-dictive signs for gastrointestinal lesions in premenopausal women with iron deficiency anemia[J].Dig Dis Sci,2008,53:3138-3144.